SOUTH SAN FRANCISCO (dpa-AFX) - Biotechnology company Jnana Therapeutics announced Tuesday that it has signed a strategic, multi-target collaboration and license agreement with Swiss drug maker Roche Group (RHHBY). The deal is to discover novel medicines that target key regulators of cellular metabolism to treat immune-mediated and neurological diseases.
Jnana would receive an upfront payment of $40 million in cash, and may receive research funding, preclinical, development and commercialization milestone payments, as well as royalties. The aggregate value of potential future payments to Jnana may exceed $1 billion.
Under the deal, Jnana will partner with Roche on discovery and preclinical development for a broad set of targets across immunology and neuroscience. Roche will further develop these and commercialize exclusively.
Copyright RTT News/dpa-AFX
© 2020 AFX News